Following recent advancements in its preclinical and commercial development, EpiAxis has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business development executive and intellectual property specialist; and Dr David Fuller, a pharmaceutical physician with extensive preclinical and clinical drug development expertise in oncology, to its board, effective immediately.

Read the Full Press Release Here